President, I ask unanimous consent that the text of the bill be printed in the Record.  There being no objection, the text of the bill was ordered to be printed in the Record, as follows:                                S. 2400       Be it enacted by the Senate and House of Representatives of      the United States of America in Congress assembled,     SECTION 1. SHORT TITLE.       This Act may be cited as the ``Expanding Cannabis Research      and Information Act''.     SEC. 2. CANNABIS RESEARCH AT THE DEPARTMENT OF HEALTH AND                    HUMAN SERVICES.       (a) National Cannabis Research Agenda.--Part B of title IV      of the Public Health Service Act (42 U.S.C. 284 et seq.) is      amended by adding at the end the following:     ``SEC. 409K. NATIONAL CANNABIS RESEARCH AGENDA.       ``Not later than 1 year after the date of enactment of the      Expanding Cannabis Research and Information Act, the Director      of NIH, in collaboration with the Director of the Centers for      Disease Control and Prevention and the Assistant Secretary      for Mental Health and Substance Use, shall develop a national      cannabis research agenda that addresses key questions and      gaps in evidence, including with respect to each of the      following:       ``(1) The efficacy of cannabis in providing therapeutic      benefits for certain priority diseases or conditions, which      may include epilepsy, multiple sclerosis-related spasticity,      chemotherapy-induced pain and discomfort, using cannabis as      an alternative to opioid analgesics for acute or chronic      pain, sleep apnea, Tourette syndrome, anxiety, post-traumatic      stress disorder, and any other disease or condition      determined to be appropriate and of importance by the      Director.       ``(2) The effect of cannabis on at-risk populations,      including children, older individuals, and pregnant or      breast-feeding women.       ``(3) The long-term effects of cannabis use, including      dose-response relationship and the connection between      cannabis use and behavioral health.       ``(4) The clinically appropriate modes of delivery of      cannabis.       ``(5) Public safety considerations related to cannabis,      including--       ``(A) variation in the potency of cannabis products;       ``(B) youth access to and use of cannabis, including      marketing, packaging, edible formulations, and flavor options      that target youth;       ``(C) risk factors for cannabis misuse;       ``(D) impaired driving related to cannabis use; and       ``(E) accidental ingestion of cannabis.''.       (b) Surveillance Activities.--Part A of title III of the      Public Health Service Act (42 U.S.C. 241 et seq.) is amended      by adding at the end the following:     ``SEC. 310B. SURVEILLANCE ACTIVITIES ON CANNABIS USE.       ``(a) In General.--The Secretary, acting through the      Director of the Centers for Disease Control and Prevention,      in collaboration with the Assistant Secretary for Mental      Health and Substance Use, the Administrator of the Centers      for Medicare & Medicaid Services, and the Director of the      Agency for Healthcare Research and Quality, shall carry out      surveillance activities to collect population-wide data on      cannabis use.       ``(b) Permissible Activities.--       ``(1) In general.--In carrying out activities under this      section, the Secretary may collect, as appropriate, with      respect to cannabis use--       ``(A) data on--       ``(i) health outcomes, including biological data;       ``(ii) health care utilization, which shall include      hospitalizations and utilization of emergency departments      related to consumption of cannabis, including among youth;       ``(iii) demographic factors associated with cannabis use;       ``(iv) the variety of products and delivery modes used; and       ``(v) other relevant health information to improve the      understanding of cannabis use in all age groups and sub-     populations; and       ``(B) data through public health surveillance systems,      surveys, questionnaires, and databases of health care      records, including, as appropriate, the Behavioral Risk      Factor Surveillance System, the Youth Risk Behavioral      Surveillance System, the Monitoring the Future health survey,      the National Survey on Drug Use and Health, or the Healthcare      Cost and Utilization Project (or any successor surveys).       ``(2) Privacy.--Any data collected under paragraph (1)      shall be collected in manner that protects personal privacy      to the extent, at a minimum, that is required under      applicable Federal and State law.''.     SEC. 3. RESCHEDULING OF MARIHUANA.       (a) In General.--Subsection (c) of schedule I of section      202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is      amended by striking paragraph (10).       (b) Schedule III.--Schedule III of section 202(c) of the      Controlled Substances Act (21 U.S.C. 812(c)) is amended by      adding at the end the following:       ``(f) Marihuana.''.     SEC. 4. CENTERS OF EXCELLENCE IN CANNABIS RESEARCH.       (a) In General.--Part B of title IV of the Public Health      Service Act (42 U.S.C. 284 et seq.), as amended by section      2(a), is further amended by adding at the end the following:     ``SEC. 409L. CENTERS OF EXCELLENCE IN CANNABIS RESEARCH.       ``(a) Designation.--       ``(1) In general.--The Director of NIH shall designate      institutions of higher education as Centers of Excellence in      Cannabis Research for the purpose of interdisciplinary      research related to cannabis and other biomedical,      behavioral, and social issues related to cannabis. No      institution of higher education may be designated as a Center      unless an application therefor has been submitted to, and      approved by, the Director of NIH. Such an application shall      be submitted in such manner and contain such information as      the Director of NIH may reasonably require. The Director of      NIH may not approve such an application unless--       ``(A) the application contains or is supported by      reasonable assurances that--       ``(i) at least 1 individual employed by the applicant--       ``(I) is registered under section 303(f) of the Controlled      Substances Act to conduct research with controlled substances      in schedule III of section 202(c) of that Act; and       ``(II) is an active participant in the cannabis research      activities of the applicant;       ``(ii) the applicant has not had a registration to conduct      research with controlled substances under section 303 of the      Controlled Substances Act denied, revoked, or suspended under      section 304 of that Act;       ``(iii) the applicant has the experience, or capability, to      conduct, through biomedical, behavioral, social, and related      disciplines, long-term research on cannabis and to provide      coordination of such research among such disciplines;       ``(iv) the applicant has available to it sufficient      personnel and facilities (including laboratory, reference,      storage, security, and data analysis facilities) to carry out      the research plan required under subparagraph (B); and       ``(v) the applicant has the capacity to conduct academic      courses and train students and professionals on appropriate      research and knowledge of cannabis; and       ``(B) the application contains a detailed 5-year plan for      research relating to cannabis.       ``(2) Geographic representation.--The Director of NIH shall      ensure geographic representation across the United States in      designating institutions of higher education as Centers of      Excellence in Cannabis Research.       ``(3) Term of designation.--A designation under this      section shall be for a period of 5 years. An institution of      higher education may reapply in accordance with the      requirements under paragraph (1) for a subsequent designation      under this section.       ``(b) Cannabis Research.--       ``(1) Grants or cooperative agreements.--       ``(A) In general.--The Director of NIH may make grants to,      or enter into cooperative agreements with, Centers that have      been designated under this section to expand the current and      ongoing interdisciplinary research and clinical trials      relating to cannabis research.       ``(B) Use of funds.--Amounts made available under a grant      or cooperative agreement under subparagraph (A) may be used      to address key questions and gaps in evidence addressed by      the national cannabis research agenda described in paragraphs      (1) through (5) of section 409K.       ``(2) Research results.--The Director of NIH shall promptly      disseminate research results under this subsection to      relevant governmental, academic, and research entities.       ``(c) Definitions.--In this section:       ``(1) Cannabis.--The term `cannabis' has the meaning given      the term `marihuana' in section 102 of the Controlled      Substances Act.       ``(2) Institution of higher education.--The term      `institution of higher education' has the meaning given the      term in section 101(a) of the Higher Education Act of      1965.''.       (b) Registration Requirements.--Section 303(f) of the      Controlled Substances Act (21 U.S.C. 823(f)) is amended by      adding after the period at the end the following: ``The      Attorney General shall register under this part practitioners      at Centers of Excellence in Cannabis Research designated      under section 409L of the Public Health Service Act to      conduct research with marihuana. No separate registration      shall be required for each individual employed by a Center of      Excellence in Cannabis Research who is conducting research      described in subsection (a)(1) of that section and in      accordance with applicable State and local laws, nor shall      separate registrations be required for distinct research      activities, including research activities related to distinct      constituent compounds of marihuana or amended protocols. The      registration shall expire on the date on which the entity is      no longer designated as such a Center of Excellence in      Cannabis Research under that section. A Center of Excellence      in Cannabis Research registered under this part may cultivate      marihuana, including any constituent component of marihuana,      to conduct research under this part if the Attorney General      has determined that the research to be conducted is for      legitimate scientific research and is consistent with      effective controls against diversion. A Center of Excellence      in Cannabis Research may contract with such additional      manufacturers of marihuana registered under this section to      meet the needs of the Center of Excellence in Cannabis      Research to the maximum extent permissible under      international treaties to which the United States is a      signatory and which govern marihuana. Before entering into      such contract, the Center of Excellence in Cannabis Research      shall submit to the Attorney General a request to enter into      the contract that includes information to demonstrate the      experience or capability of the contractor to conduct such      cultivation and assurances that the contractor will comply      with the provisions of this Act. Not later than 60 days after      the date on which the request is submitted, the request shall      be deemed to be approved by the Attorney General, unless the      Attorney General determines that the granting of such request      is inconsistent with the public interest. A Center of      Excellence in Cannabis Research registered under this section      may purchase or acquire commercially available marihuana for      the purpose of research described in section 409L(a)(1) of      the Public Health Service Act in accordance with the law of      the State in which the transaction occurs. No Federal funds      may be used by the Center of Excellence in Cannabis Research      for such purchase or acquisition.''.                                 ______                                       By 